Literature DB >> 33956069

Eculizumab and aHUS: to stop or not.

Robert A Brodsky1.   

Abstract

Entities:  

Year:  2021        PMID： 33956069      PMCID： PMC8109016          DOI： 10.1182/blood.2020010234

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  9 in total

1.  Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update.

Authors:  Gianluigi Ardissino; Ilaria Possenti; Francesca Tel; Sara Testa; Stefania Salardi; Vito Ladisa
Journal:  Am J Kidney Dis       Date:  2015-07       Impact factor: 8.860

2.  Eculizumab cessation in atypical hemolytic uremic syndrome.

Authors:  Samuel A Merrill; Zachary D Brittingham; Xuan Yuan; Alison R Moliterno; C John Sperati; Robert A Brodsky
Journal:  Blood       Date:  2017-05-01       Impact factor: 22.113

3.  Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.

Authors:  Fadi Fakhouri; Marc Fila; François Provôt; Yahsou Delmas; Christelle Barbet; Valérie Châtelet; Cédric Rafat; Mathilde Cailliez; Julien Hogan; Aude Servais; Alexandre Karras; Raifah Makdassi; Feriell Louillet; Jean-Philippe Coindre; Eric Rondeau; Chantal Loirat; Véronique Frémeaux-Bacchi
Journal:  Clin J Am Soc Nephrol       Date:  2016-10-31       Impact factor: 8.237

Review 4.  Complementopathies and precision medicine.

Authors:  Eleni Gavriilaki; Robert A Brodsky
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

Review 5.  Haemolytic uraemic syndrome.

Authors:  Fadi Fakhouri; Julien Zuber; Véronique Frémeaux-Bacchi; Chantal Loirat
Journal:  Lancet       Date:  2017-02-25       Impact factor: 79.321

6.  Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.

Authors:  Russell P Rother; Scott A Rollins; Christopher F Mojcik; Robert A Brodsky; Leonard Bell
Journal:  Nat Biotechnol       Date:  2007-11       Impact factor: 54.908

7.  Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

Authors:  C M Legendre; C Licht; P Muus; L A Greenbaum; S Babu; C Bedrosian; C Bingham; D J Cohen; Y Delmas; K Douglas; F Eitner; T Feldkamp; D Fouque; R R Furman; O Gaber; M Herthelius; M Hourmant; D Karpman; Y Lebranchu; C Mariat; J Menne; B Moulin; J Nürnberger; M Ogawa; G Remuzzi; T Richard; R Sberro-Soussan; B Severino; N S Sheerin; A Trivelli; L B Zimmerhackl; T Goodship; C Loirat
Journal:  N Engl J Med       Date:  2013-06-06       Impact factor: 91.245

8.  The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.

Authors:  Gema Ariceta; Bradley P Dixon; Seong Heon Kim; Gaurav Kapur; Teri Mauch; Stephan Ortiz; Marc Vallee; Andrew E Denker; Hee Gyung Kang; Larry A Greenbaum
Journal:  Kidney Int       Date:  2020-12-08       Impact factor: 10.612

9.  Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study.

Authors:  Fadi Fakhouri; Marc Fila; Aurélie Hummel; David Ribes; Anne-Laure Sellier-Leclerc; Simon Ville; Claire Pouteil-Noble; Jean-Philippe Coindre; Moglie Le Quintrec; Eric Rondeau; Olivia Boyer; François Provôt; Djamal Djeddi; William Hanf; Yahsou Delmas; Ferielle Louillet; Annie Lahoche; Guillaume Favre; Valérie Châtelet; Emma Allain Launay; Claire Presne; Ariane Zaloszyc; Sophie Caillard; Stéphane Bally; Quentin Raimbourg; Leïla Tricot; Christiane Mousson; Aurélie Le Thuaut; Chantal Loirat; Véronique Frémeaux-Bacchi
Journal:  Blood       Date:  2021-05-06       Impact factor: 22.113
  9 in total
  2 in total

1.  Serum C1q Levels Have Prognostic Value for Sepsis and are Related to the Severity of Sepsis and Organ Damage.

Authors:  Huan Li; Juanjuan Chen; Yuanhui Hu; Xin Cai; Dongling Tang; Pingan Zhang
Journal:  J Inflamm Res       Date:  2021-09-10

2.  Application of C5 inhibitors in glomerular diseases in 2021.

Authors:  Alexis Werion; Eric Rondeau
Journal:  Kidney Res Clin Pract       Date:  2022-03-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.